Skip to content
Sign up to our: Newsletter | Newsfeeds

New drugs to treat colorectal cancer and cystic fibrosis available in Wales

This press release was published under the 2011 - 2016 Welsh government

Medicines to treat colorectal cancer and cystic fibrosis will be routinely available on the Welsh NHS, Health and Social Services Minister Mark Drakeford announced today.
Wednesday 30 December 2015

Cetuximab will be available as an option for the first-line treatment of patients with certain types of colorectal cancer following a positive recommendation by the All Wales Medicines Strategy Group (AWMSG).

It has been approved for use in combination with chemotherapy or FOLFOX (folinic acid, fluoroucil and oxaliplatin).

Cetuximab has not been routinely available in Wales following guidance issued by the National Institute for Health and Care Excellence (NICE) in 2009. But a growing body of evidence demonstrating benefits for certain types of colorectal cancer and the manufacturer’s willingness to engage with Wales’ appraisal process and take part in Wales’ patient access scheme led to AWMSG’s positive recommendation at its December meeting.  

The Minister has also approved AWMSG’s recommendation that Ivacaftor (Kalydeco®), which is used to treat cystic fibrosis, should be made available to a wider range of individuals suffering from the condition.

Ivacaftor is the first medicine to treat the underlying cause of cystic fibrosis – other treatments only alleviate the symptoms of the condition – and represents a significant step forward in the treatment of cystic fibrosis. It will be available for children aged six and over who have one of a number of specific gene mutations associated with cystic fibrosis.

Cystic fibrosis is the most common, life-limiting, inherited disease in the UK, affecting approximately one in 2,500 babies.

Professor Drakeford said:

“In Wales, all medicines approved by NICE or the All Wales Medicines Strategy Group are made available routinely in NHS Wales.

“Following these two latest positive recommendations from AWMSG, I’m pleased to announce I have approved the use of cetuximab as a treatment for colorectal cancer and ivacaftor – Kalydeco – to treat cystic fibrosis for use in the Welsh NHS.”



About social bookmarking



Health and social services 30 December 2015 Programme for Government - Healthcare Mid Wales North Wales South East Wales South West Wales

News by date

June 2018
<< May    
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30  
Follow us on